 EX-10.2 2 y42620exv10w2.htm EX-10.2: AMENDMENT NO. 1 TO THE AMENDED AND 
RESTATED SEVERANCE AGREEMENT


 

Exhibit 10.2


AMENDMENT NO. 1 TO
AMENDED AND RESTATED SEVERANCE AGREEMENT

     AMENDMENT NO. 1 (the Amendment), dated as of November 6, 2007, to 
that certain AMENDED AND RESTATED SEVERANCE AGREEMENT (the Agreement) by 
and between Enzon Pharmaceuticals, Inc. (the Company) and Ralph del Campo 
(Executive) dated as of May 7, 2004.

     The undersigned parties hereby desire to amend the Agreement in the 
manner set forth herein. All capitalized terms used herein but not 
otherwise defined shall have the meanings ascribed to such terms in the 
Agreement.

     NOW, THEREFORE, in consideration of the premises and the mutual 
agreements contained herein and for other good and valuable consideration 
the sufficiency of which is hereby acknowledged, the undersigned hereby 
agree as follows:

1. Section 2 of the Agreement is hereby amended by deleting subsection (c) 
in its entirety and inserting in lieu thereof the following:

  	  	in the event of a Change in Control defined in Section 7(c)(i)-(vi), 
Executive shall receive cash payments equal to TWO (2) TIMES the sum of the 
following: (i) his or her Base Salary at the time of such termination and 
(ii) the Target Bonus (based on the Base Salary immediately prior to such 
termination) for the fiscal year in which such termination occurs;

2. Except as expressly amended, modified and supplemented hereby, the 
provisions of the Agreement are and will remain in full force and effect.

     IN WITNESS WHEREOF, the parties hereto have executed this Agreement as 
of the date first above written.
  	  	 
RALPH DEL CAMPO 	  	ENZON PHARMACEUTICALS, INC.
  	  	 
/s/ Ralph del Campo 
  	By: /s/ Jeffrey H. Buchalter
 
  	 
  	  	 
Name: Ralph del Campo
Title: Executive Vice President, Technical Operations
  	Name: Jeffrey H. Buchalter
Title: Chairman, President and Chief Executive Officer

 